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Background: Basigin, which has four isoforms, has been demonstrated to be involved in progression of various
human cancers. The aim of this study was to examine the prognostic value of basigin-2 protein expression in
epithelial ovarian cancer. Furthermore, the function of basigin-2 in ovarian cancer was further investigated in cell
culture models.
Methods: Immunohistochemistry staining was performed to investigate basigin-2 expression in a total of 146
ovarian tissue specimens. Kaplan Meier analysis and Cox proportional hazards model were applied to assess the
relationship between basigin-2 and progression-free survival (PFS) and overall survival (OS). Real-time PCR, RT-PCR
and western blot were used to explore basigin-2, basigin-3 and basigin-4 expression in ovarian cancer cell lines and
tissues. To evaluate possible contributions of basigin-2 to MMP secretion and cell migration and invasion, the
overexpression vectors pcDNA3.1-basigin-2 and basigin-2 siRNA were transfected into HO-8910 and HO-8910 PM
cells respectively.
Results: High basigin-2 expression was associated with lymph-vascular space involvement, lymph node metastasis
and poor prognosis of epithelial ovarian cancer. Multivariate analyses indicated that basigin-2 positivity was an
independent prognostic factor for PFS (P = 0.006) and OS (P = 0.019), respectively. Overexpression of basigin-2
increased the secretion of MMP-2/9 and cancer cell migration and invasion of HO-8910 cells, whereas knockdown
of basigin-2 reduced active MMP-2/9 production, migration and invasion of HO-8910 PM cells.
Conclusions: The expression of basigin-2 might be an independent prognostic marker and basigin-2 inhibition
would be a potential strategy for epithelial ovarian cancer patients, especially in inhibiting and preventing cancer
cell invasion and metastasis.
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Table 1 Relationship between basigin-2 expression with




Low (n%) High (n%)
Age 0.683
<60 95 34 (35.8) 61 (64.2)
≥60 51 20 (39.2) 31 (60.8)
FIGO stage 0.412
I+II 48 20 (41.7) 28 (58.3)
III+IV 98 34 (34.7) 64 (65.3)
Grade 0.478
G1 27 12 (44.4) 15 (55.6)
G2 45 18 (40.0) 27 (60.0)
G3 74 24 (32.4) 50 (67.6)
Histological type 0.564
Serous 64 22 (34.4) 42 (65.6)
Nonserous 82 32 (39.0) 50 (61.0)
LVS involvement 0.012*
Negative 120 50 (41.7) 70 (58.3)
Positive 26 4 (15.4) 22 (84.6)
Lymph node metastasis 0.017*
Negative 111 47 (42.3) 64 (57.7)
Positive 35 7 (20.0) 28 (80.0)
*P < 0.05, LVS lymph-vascular space.
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Ovarian cancer is the most lethal gynecologic malignancy
among women in many countries [1]. Epithelial ovarian
cancer is the most common ovarian cancer and accounts
for approximately 70% of all ovarian malignant diseases. It
is the sixth most common cancer and the fifth leading
cause of cancer-related death in women worldwide [2].
Being largely asymptomatic, almost 70% of cases are
at an advanced stage at diagnosis [3]. Despite significant
advances in surgery and chemotherapy over the last few
decades, therapeutic failure and disease progression are
still quite frequent [4,5]. Therefore, there is an urgent
requirement for new biomarkers for ovarian cancer, so as
to develop better early diagnostic and therapeutic strategies.
Basigin, also known as CD147, extracellular matrix
metalloproteinase inducer (EMMPRIN), neurothelin,
5A11, gp42, OX-47, and CE9, is a widely expressed
integral plasma membrane glycoprotein that belongs
to the immunoglobulin superfamily [6]. It is a highly
glycosylated 58-kDa transmembrane protein that has
four isoforms [7]. It turned out to be multifunctional
and involved in various physiological processes such as
fetal development, reproduction, T cell differentiation, and
neural and retinal functions [6,8,9]. Increased expression
of basigin has been found in several human tumors
suggesting a role in human carcinogenesis. Moreover, it
has been shown that higher expression of basigin was
associated with poor prognosis of cancer patients and could
serve as an independent predictor of poor survival in
cancer [10-18]. The most life-threatening aspects of the
oncogenic process are invasion and metastasis. Basigin has
been shown to induce the production of several Matrix
metalloproteinases (MMPs) which play an important role
in tumor invasion and metastasis formation [19-32].
Basigin has four isoforms, namely basigin-1, basigin-2,
basigin-3 and basigin-4. The basigin-1 transcript
(NM_001728) is specific expressed on retina tissue and
encodes a long three Ig-like domains in its extracellular
portion [33]. The basigin-2 transcript (NM_198589) is
the most predominant splice variant, encoding two Ig-
like extracellular domains and being well-known as
basigin/CD147/EMMPRIN [7]. Basigin-3 (NM_198590)
and basigin-4 (NM_198591) are the other two short
isoforms, encoding only one Ig-like domain in its extracel-
lular portion, respectively. Basigin-4 was reported to
overexpress in cervical cancer and promote proliferation
of cervical cancer cell [34]. Our previous study showed
Basigin-3 and Basigin-4 were up-regulated in hepatocellu-
lar carcinoma tissues and Basigin-3 exerted an inhibitory
function to proliferation and invasion of HCC [35].
This is the first report that has examined the expression
patterns of basigin and its isoforms in ovarian cancer
tissues and cell lines. We also investigated the correlations
between basigin-2 expression and various clinic pathologicparameters, and its prognostic value for survival of patients
with epithelial ovarian cancer. Furthermore, we determined
the functional roles of basigin-2 in ovarian cancer cell lines.
The results presented here help to evaluate the suitability of
basigin-2 as therapeutic target.
Methods
Patients and tissue samples
This study was approved by the Ethics Committee of the
Fourth Military Medical University. For real-time PCR
analysis, we collected data on 98 patients, including epithe-
lial ovarian cancer (71 cases) and normal ovary (27 cases),
treated at Xijing Hospital between November 2009 and
June 2011. For immunohistochemical analysis, 146 patients
with epithelial ovarian cancer who underwent surgical
treatment at Xijing Hospital between May 2004 and July
2006 were included in this study. Patients whose cause of
death remained unknown were excluded from our study.
Ages of the 146 patients with ovarian carcinoma ranged
from 26 to 79 years (mean, 52.8 years) and clinicopathologi-
cal characteristics of the tumor sets are described in Table 1.
Clinical data were obtained from clinical databases and
tumors were staged according to International Federation
of Gynecology and Obstetrics (FIGO) guidelines. None of
the patients underwent chemotherapy or other adjuvant
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tive, platinum-based chemotherapy, but no radiotherapy.
Informed consent was obtained from each patient before
sample collection. The follow-up interval was calculated
from the date of surgery to the date of death or last clinical
evaluation. The follow-up time was from the date of sur-
gery to March 2012, and the median time was 36 months
(7 to 82 months). Eighty-five (58%) of these relapsed and
108 (74%) died during the course of the follow-up period.
The duration of overall survival was measured from the
date of diagnosis to death or censored at the date of last
follow-up. Tumour progression was defined based on
clinical, radiological or histological diagnosis.
Immunohistochemistry
Paraffin-embedded 4 μm-thick sections were deparaffinized,
heated in citrate buffer (0.01 M), treated with 0.3% H2O2
(v/v), and re-hydrated. After blocking, the sections were
incubated with basigin-2 antibody (HAb18, 1:200 dilution)
in a humid chamber at room temperature for 1 h.
HAb18, a monoclonal antibody against the Ig-C2 domain
(specific to basigin-2), was produced and characterized
in our laboratory [36,37]. The sections were rinsed and
incubated for 30 min with the biotinylated second
antibody. After washing, the slides were exposed to
diaminobenzidine, and counterstained with hematoxylin.
After serial dehydration, the slides were mounted for
microscopic examination. Before staining the biopsies of
selected patients, we optimized our staining procedure by
comparing different antigen retrieval methods and testing
different antibody dilutions in epithelial ovarian cancer
biopsies. As positive controls epithelial ovarian cancer
tissue that showed positive staining in earlier staining
procedures was used. As negative control for the staining
procedure, the primary antibody was omitted. The intensity
of basigin-2 staining was scored as 0 (no signal), 1 (weak), 2
(moderate), and 3 (marked). Percentage scores were
assigned as 1, 1-25%; 2, 26-50%; 3, 51-75%; and 4, 76-100%.
The scores of each tumor sample were multiplied to give a
final score of 0–12, and the tumors were finally determined
as negative (−), score 0; lower expression (+), score ≤4;
moderate expression (++), score 5–8; and high expression
(+++), score ≥9. In this study, we grouped all of the samples
into the high expression group (++ or +++) and the
low expression group (− or +) according to the protein
expression. Two of the pathologists, without prior
knowledge of the clinical data, independently graded
the staining intensity in all cases.
Cell lines
3-AO, SKOV-3, HO-8910 and HO-8910 PM (a highly
metastatic cell line derived from HO-8910) ovarian
cancer cells were purchased from the Cell Bank of Type
Culture Collection of the Chinese Academy of Sciences(Shanghai, China) [38]. A-2780 cells were purchased from
the American Type Culture Collection. All cell lines were
cultured using standard protocols.
Cell culture and transfection
The cells were maintained at 37°C under 5% CO2 in
DMEM containing 10% (v/v) FBS. The coding regions of
basigin-2 were inserted into pcDNA3.1 (Clontech). We
transfected the plasmids into the cells using Lipofectamine
2000™ reagent (Invitrogen, USA) and incubated the cells
for 48 h before analysis. The expression of basigin-2 protein
was confirmed by western blot analysis using HAb18.
Gene silencing using siRNA
HO-8910 PM cells were transfected with basigin-2
siRNA by the Lipofectamine™ 2000 (Invitrogen, USA)
according to the manufacturer’s instructions. A nonspecific
control was used as non-targeting siRNAs. Twenty-four
hours after transfection, transfected cells were examined for




To determine the enzyme activities of MMP-2 and MMP-9,
media derived from the ovarian cancer cells cultured for
48 hours were used for the gelatin zymography. Culture
media were subjected to a 10% SDS-PAGE, in which 1 mg/
ml gelatin (type A from porcine skin) had been incorpo-
rated. After electrophoresis, the gels were washed for 1 h in
a buffer containing 2.5% Triton X-100 and then incubated
overnight in a digestion buffer containing calcium and zinc
at 37°C with constant stirring for 24 h. Then, gels were
stained with 0.25% Coomassie Brilliant Blue R-250
(Sigma, USA) and distained in 7.5% acetic acid with 20%
methanol. MMP-2 and MMP-9 activities were quantified
by densitometry using Quantity One software.
RT-PCR
Total RNA was harvested from cultured cells or tissues
using the RNeasy minikit (Qiagen, Germany) and reverse
transcribed into cDNA using the PrimeScript reverse
transcription-PCR (RT-PCR) kit (TaKaRa, Japan). PCRs
were performed using Ex Taq HS (TaKaRa) with the
following program: 94°C for 2 min; 30 cycles of 94°C for
30 s, 56°C for 30 s, and 72°C for 60 s; and a final step of
10 min at 72°C. PCR products were analyzed using
agarose gel electrophoresis and cloned into the pMD18-T
(TaKaRa) vector for sequencing. The following primers
were used: for basigin-2, 50-ATGGCGGCTGCGCTGTTC
GTGCTG-30 (forward); 50-GGCCTCCATGTTCAGGTTC
TCAAT-30 (reverse); for basigin-3 and basigin-4, 50-GGCT
TAGTCTGCGGTCCTCTTGCA-30 (forward); 50-GGCCT
CCATGTTCAGGTTCTCAAT-30 (reverse); for β-actin,




TaqMan primer and probe pairs specific to basigin
variants and β-actin were synthesized by Invitrogen
(Shanghai, China). Real-time quantitative RT-PCR was
performed using the Stratagene Mx3005p multiplex
quantitative PCR system (La Jolla, CA) and Premix Ex Taq
reagent (TaKaRa). The cycling program was 94°C for 2 min
and 40 cycles of 94°C for 15 s, 58°C for 20 s, and 72°C for
20 s. The results were normalized as the ratio of absolute
mRNA copy numbers of basigin variants to those of
β-actin, which were calculated from standard curves that
were obtained from dilutions of precisely quantified
template plasmid. The following primers were used: for
basigin-2, 50-TCGCGCTGCTGGGCACC-30 (forward); 50-
TGGCGCTGTCATTCAAGGA-30 (reverse), 50FAM-CCGG




TAMRA30 (TaqMan probe); for basigin-4, 50-GTTGCTGA
GAGTCTGGGTTTACG-30 (forward); 50-GGGAGGAAGA
CGCAGGAGTAC-30 (reverse), 50 FAM-CCAAGAAAGGG





Cells were lysed in lysis buffer containing protease
inhibitor cocktail. Protein concentration was determined
using a BCA protein assay kit (Pierce, USA). Equal
amounts of protein lysate were electrophoretically sepa-
rated on 10% sodium dodecyl sulfate-polyacrylamide gels
and transferred to PVDF membranes (Millipore, USA). The
membranes were blocked with 1% BSA for 2 h at room
temperature and incubated with HAb18 and β-tubulin
(Santa Cruz, USA), followed by horseradish peroxidase-
conjugated secondary antibody. Protein expression levels
were quantified using the software Quantity One to detect
intensity of the protein bands.
Wound-healing assay
Cell migration was measured by the in vitro scratch
wound-healing assay. Ovarian cancer cells were incubated
in 24-well plates and a small wound area was made in the
confluent monolayer with a scraper. Then, the cells were
rinsed two times with PBS and fresh culture medium was
added. Wound closure was monitored at various time
points by observation under a microscope, and the degree
of cell migration was quantified by the ratio of gap distance
at 36 h to that at 0 h. Experiment was repeated three times.Cell migration and invasion assays
The invasive and migratory potential of cells was
evaluated using Transwell chambers with 8 μm pores
(BD Biosciences, USA). For cell invasion assays, after
24 h transfection, 3.0 × 105 cells in serum free medium
were added to each upper insert pre-coated with matrigel
matrix (BD Biosciences, USA). The bottom chamber
contained standard medium with 10% FBS. After 48 h
incubation, non-invasion cells on the upper surface of the
filters were removed gently by a cotton-tip swab, and
invaded cells on the lower membrane surface were fixed in
methanol, stained with 0.1% crystal violet, photographed,
and counted. Cell migration assay was performed according
to the protocol described above, except that the cells were
added into the inserts with 24-hour incubation without
matrix gel pre-coated. Each experiment was carried out in
triplicate wells and repeated at least three times.
Statistical analysis
The correlations between immunohistochemical expression
and the clinical variables were evaluated by the χ2-test or
Fisher’s exact test, as appropriate. PFS and OS curves were
calculated with the Kaplan-Meier method and were
analyzed with the log-rank test. Cox proportional hazards
modeling of factors potentially related to survival was
performed to identify factors that might have a significant
influence on survival. One-way ANOVA was used to
compare the MMP production, transfilter cell number,
fluorescence signals and grayscale value in different groups.
P < 0.05 was considered statistically significant. All analyses
were performed with SPSS 12.0 for Windows.
Results
Clinical significance of basigin-2 expression in epithelial
ovarian cancer
We examined the basigin-2 expression in epithelial ovarian
cancer by immunohistochemical staining, using a total of
146 surgical specimens. As shown in Figure 1A, the
immunoreactivity of basigin-2 was detected at variable
levels, and was localised in the cytomembrane of
tumor cells. The correlation of basigin-2 expression
with clinicopathological features was shown in Table 1.
Basigin-2 expression was positively correlated with
lymph-vascular space involvement (P = 0.012), lymph
node metastasis (P = 0.017), but not with age, FIGO stage,
degree of differentiation, or Histological type.
The each of PFS and OS curves calculated using the
Kaplan-Meier method according to basigin expression
was shown in Figure 1B and 1C (progression-free time,
P < 0.001, Figure 1B; overall survival time, P = 0.001,
Figure 1C). By using univariate Cox proportional ana-
lysis, basigin-2 expression was statistically correlated
to progression-free survival (P < 0.001, Table 2) and overall
survival (P = 0.002, Table 2). By using multivariate Cox
Figure 1 Basigin-2 expression level and its prognostic effects in epithelial ovarian cancer. A Representative images of Basigin-2 protein
expression in paraffin-embedded tissue from 146 patients with epithelial ovarian cancer (−, +, ++, +++). Scale bars = 0.1 mm. B The progression-
free survival curves for the high-basigin-2 expression group (n = 92) and the low-basigin-2 expression group (n = 54). The progression-free
survival rates between the two groups showed significantly different (P < 0.001). C The overall survival curves for the high-basigin-2 expression
group (n = 92) and the low-basigin-2 expression group (n = 54). The overall survival rates between the two groups showed significantly different
(P = 0.001). D-F Overexpression of basigin variants in epithelial ovarian cancer tissues. The expression levels of basigin variants were calculated as
the log10 value of the normalized ratio.
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variables and basigin-2 expression and FIGO staging were
independent factors of progression-free and overall survival
prognosis predictions (Tables 2 and 3).
Differential expression of basigin mRNA variants in
ovarian normal and cancer tissues
27 normal and 71 tumor samples were used to analyze
basigin-2, basigin-3 and basigin-4 mRNA expression by
real-time quantitative PCR assay (Figure 1D-F). Expression
level was shown as a ratio between basigin-2, basigin-3 and
basigin-4, the reference gene β-actin to correct for the
variation in the amounts of RNA. The results indicated
that mRNA levels of basigin-2 and basigin-4 were
significantly different between the cancer and normal
samples. Expressions of basigin-2 and basigin-4 mRNAs
in ovarian normal tissues were lower than that in cancer
tissues (P < 0.001 and P = 0.0129, respectively), whereasmRNA level of basigin-3 showed no significant difference
between ovarian normal and cancer tissues (P = 0.2703),
as shown in Figure 1D-F.
Basigin-2 protein expression in ovarian cancer cell lines
We used western blot analysis to characterize protein
expression of basigin-2 in five ovarian cancer cell lines.
Basigin-2 was detectable in all these five cell lines, with
highest expression in HO-8910 PM cells. Expression of
basigin-2 protein in HO-8910 cell line was lower than
that in its subline cell line HO-8910 PM (a highly
metastatic cell line derived from HO-8910), as shown
in Figure 2A and 2B.
Basigin-2, Basigin-3 and Basigin-4 mRNA expression in
ovarian cancer cell lines
RT-PCR was performed to determine whether basigin
mRNA variants were expressed in ovarian cancer cell






HRa 95% CIb HRa 95% CIb
Age <60
≥60 1.131 0.779-1.640 0.518 – – –
FIGO stage I+II
III+IV 1.882 1.261-2.809 0.002* 1.710 1.144-2.557 0.009*
Grade G1
G2 1.171 0.686-1.997 0.563 – – –
G3 1.419 0.864-2.330 0.166 – – –
Histological type Serous
Nonserous 0.852 0.596-1.218 0.380 – – –
LVS involvement Negative
Positive 1.944 1.246-3.033 0.003* 1.410 0.935-2.127 0.101
Lymph node metastasis Negative
Positive 1.638 1.091-2.461 0.017* 1.578 1.001-2.488 0.050
Basigin-2 Low
High 2.046 1.388-3.017 <0.001* 1.758 1.179-2.619 0.006*
PFS progression-free survival, aHR = hazard ratio, bCI = confidence interval, *P < 0.05, LVS lymph-vascular space.
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basigin-4 were detectable in all these five cell lines
(Figure 2C). We used real-time PCR analysis to characterize
mRNA expression of basigin-2, basigin-3 and basigin-4 in
five ovarian cancer cell lines. Expression of basigin-2 and
basigin-4 mRNA in HO-8910 cell line was lower than that
in its subline cell line HO-8910 PM, as shown in Figure 2D



















OS overall survival, aHR = hazard ratio, bCI = confidence interval, *P < 0.05, LVS lymno significant difference between HO-8910 cells and
HO-8910PM cells (P > 0.05).
Effects on cellular invasiveness/migration and MMP-9/
MMP-2 expressions of HO-8910 cells after transfection
with basigin-2
HO-8910 cells were either untransfected (blank), or




Ib HRa 95% CIb
.752 0.338 - - -
.713 0.004* 1.641 1.089-2.471 0.018*
.969 0.598 - - -
.116 0.332 - - -
.265 0.485 - - -
.555 0.012* 1.475 0.974-2.232 0.066
.924 0.007* 1.530 0.961-2.435 0.073
.785 0.002* 1.622 1.084-2.429 0.019*
ph-vascular space.
Figure 2 Expression levels of basigin-2, basigin-3 and basigin-4 in ovarian cancer cells. A-B Western blot analysis determining the relative
protein expression levels of basigin-2 in ovarian cancer cells. Basigin-2 protein expression levels were quantified using Quantity One normalized
against tubulin levels. C RT-PCR analysis of basigin-2, basigin-3 and basigin-4 mRNA expression levels in ovarian cancer cells. D-F Real-time PCR
analysis determining the relative mRNA expression levels of basigin-2, basigin-3 and basigin-4 in ovarian cancer cells. Columns mean derived from
at least three independent experiments, bars, SD. Statistical analysis was done using Student’s t tests. *P < 0.05, significant.
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cells, western blot analysis was performed to analyze the
expression levels of basigin-2 protein. As shown in
Figure 3A and Figure 3B, the expression of basigin-2
protein was increased in pcDNA3.1-basigin-2-transfected
cells compared with pcDNA3.1-transfected cells and
untransfected cells (P < 0.05). Next, we employed gel-
atin zymography to analyze the effect of basigin-2
overexpression on MMP-2 and MMP-9 enzyme activities.
We observed that MMP-2 and MMP-9 gelatinase activities
in the culture media of pcDNA3.1-basigin-2-transfected
HO-8910 cells were substantially higher than in cells
transfected with control cells (Figure 3C and Figure 3D,
P < 0.05).
Cellular invasiveness and migration were analyzed by
both Transwell and wound healing assays. HO-8910 cells
that were transfected with the pcDNA3.1-basigin-2 plas-
mid exhibited a significant increase in cellular migration
as compared with control cells (Figure 3E-3H). Invasionis another important step for metastasis. To investigate
the effects of pcDNA3.1-basigin-2 transfection on cell
invasion, we determined the ability of pcDNA3.1-basigin-2-
transfected cells to invade through Matrigel in Transwell
chambers. As shown in Figure 3I and 3J, HO-8910 cells
transfected with pcDNA3.1-basigin-2 displayed much
higher invasive capability compared with control cells as
evidenced by increased number of cells invading through
the matrigel.
Effects on cellular invasiveness/migration and MMP-9/
MMP-2 expressions of HO-8910PM cells after transfection
with basigin-2 siRNA
HO-8910PM cells were either untransfected (blank), or
transfected with nonspecific siRNA (control) or basigin-2
siRNA (siRNA), as shown in Figure 4. After transfection of
cells, western blot analysis was performed to analyze
the expression levels of basigin-2 protein. As shown in
Figure 4A and Figure 4B, the expression of basigin-2
Figure 3 Effects on cellular invasiveness/migration and MMP-9/MMP-2 expressions of HO-8910 cells after transfection with basigin-2.
HO-8910 cells were either untransfected (blank), or transfected with pcDNA3.1 (control) or pcDNA3.1-basigin-2 (basigin-2). A-B Western blot
demonstrated basigin-2 protein levels were significantly increased after transfection with basigin-2. C-D HO-8910 cells were incubated for 24 h
and conditioned media were used for the measurement of MMP-2 and MMP-9 protein levels by gelatin zymography. Zymographic analysis
showed increased MMP-2 and MMP-9 activity in basigin-2-transfected HO-8910 cells. E-F Wound healing assay was performed on monolayers of
HO-8910 cells transfected with pcDNA3.1-basigin-2. The wound gaps were measured at six reference points along the wound, and the results
were expressed as the average wound gap. G-H Overexpression of basigin-2 in HO-8910 cells resulted in an increase in cellular migrate capacity.
I-J Overexpression of basigin-2 in HO-8910 cells resulted in an increase in cellular invasive capacity. Scale bars = 0.5 mm (E). Scale bars = 0.1 mm
(G, I). Statistical significance was assessed using one-way ANOVA. Data are presented as mean ± SD for three independent experiments. *P < 0.05,
statistically significant difference.
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cells compared with control siRNA-transfected cells
and untransfected cells (P < 0.05). Next, we employed
gelatin zymography to analyze the effect of silencing
basigin-2 on MMP-2 and MMP-9 enzyme activities.
We observed that MMP-2 and MMP-9 gelatinase activities
in the culture media of basigin-2 siRNA-transfected
HO-8910PM cells were substantially lower than in cells
transfected with control cells (Figure 4C and Figure 4D,
P < 0.05).
Cellular invasiveness and migration were analyzed by
both Transwell and wound healing assays. The results
showed a significant reduction in motility of basigin-2
siRNA-transfected cells compared with the control groups(Figure 4E-4H). Invasion is another important step for
metastasis. To investigate the effects of basigin-2 siRNA
transfection on cell invasion, we determined the ability of
basigin-2 siRNA-transfected cells to invade through
Matrigel in Transwell chambers. As shown in Figure 4I
and 4J, a significant reduction in the number of invading
cells was observed for siRNA-transfected cells after 24 h
compared with the control cells.
Discussion
Previous studies have shown that basigin is one of the
most commonly up-regulated genes in human tumors.
Importantly, its expression is often correlated with
tumor metastasis and poor prognosis [10-18]. There are
Figure 4 Effects on cellular invasiveness/migration and MMP-9/MMP-2 expressions of HO-8910PM cells after transfection with basigin-2
siRNA. HO-8910PM cells were either untransfected (blank), or transfected with nonspecific siRNA (control) or basigin-2 siRNA (siRNA). A-B Western blot
demonstrated basigin-2 protein levels were significantly inhibited by basigin-2 siRNA. C-D HO-8910PM cells were incubated for 24 h and conditioned
media were used for the measurement of MMP-2 and MMP-9 protein levels by gelatin zymography. Zymographic analysis showed decreased MMP-2
and MMP-9 activity in HO-8910PM cells transfected with basigin-2 siRNA. E-F Wound healing assay was performed on monolayers of HO-8910PM cells
transfected with basigin-2 siRNA. The wound gaps were measured at six reference points along the wound, and the results were expressed as the
average wound gap. G-H Suppression of basigin-2 expression in HO-8910PM cells resulted in significant reduction in cellular migration. I-J Suppression
of basigin-2 expression in HO-8910PM cells resulted in significant reduction in cellular invasiveness. Scale bars = 0.5 mm (E). Scale bars = 0.1 mm (G, I).
Statistical significance was assessed using one-way ANOVA. Data are presented as mean ± SD for three independent experiments. *P < 0.05,
statistically significant difference.
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the survival and progression of ovarian cancer, and is
considered as a biomarker of poor outcome [39-41].
However, some results show that basigin is a significant
indicator of a favorable prognosis of ovarian cancer
[42,43]. In the present study, we described the relationship
between basigin-2 expression and clinicopathological
parameters of 146 cases of epithelial ovarian cancer with
immunohistochemical analysis. Our results indicated that
high basigin-2 expression was significantly correlated with
lymph-vascular space involvement and lymph node me-
tastasis, suggesting that its expression might be important
for the acquirement of malignant potential in epithelial
ovarian cancer. Moreover, high basigin-2 expression wasassociated with significantly shorter overall survival and
progression-free survival in epithelial ovarian cancer. We
evaluated prognostic value of various factors by univariate
and multivariant COX proportional analysis, and found
that basigin-2 expression was significantly associated with
both overall survival and progression-free survival.
These results led us to believe that basigin-2 might be
used as a candidate biomarker for epithelial ovarian
cancer diagnosis and therapy.
As far as we know, this is the first report that we
checked basigin variants expression level in ovarian
cancer tissues and cell lines. In the present study, we
showed that basigin-2 and basigin-4 mRNA expressions
determined by real-time quantitative PCR were significantly
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tissues. We also showed that basigin-2, basigin-3 and
basigin-4 were detectable by real-time quantitative
PCR assays in ovarian cancer cell lines. We found basigin-2
and basigin-4 are up-regulated in high metastasis
ovarian cancer cell line HO-8910PM comparing to its
parent cell line HO-8910. Cause mRNA level of
basigin-2 was much higher than basigin-4 in ovarian
cancer (>100 fold to basigin-4), we focused our further
study on basigin-2. Diagnosis of epithelial ovarian cancer
usually occurs when the cancer has already progressed to
the advanced stages [3]. Invasion and metastasis are
characteristic features and the main factors related to the
poor prognosis in patients with epithelial ovarian cancer.
Therefore, it is important to understand the molecular
mechanisms involved in the pathogenesis and progression
of metastasis to the development of novel therapies
to treat epithelial ovarian cancer. The major mediators
of basement membrane degradation are the matrix
metalloproteinases (MMPs) [26,44]. The MMPs, a family of
zinc-dependent endopeptidases, play a prominent role in in
extracellular matrix degradation associated with cancer cell
invasion and metastasis [45-48]. MMP-2 and MMP-9, in
particular, have been found to be specifically associated
with ovarian cancer metastasis [49,50]. Basigin has been
shown to promote the invasion and migration of tumor
cells by induction of MMP activities which is regulated by
basigin isoforms and glycosylation patterns [35,51]. In order
to further investigate the effects of basigin-2 on ovarian
cancer progression, pcDNA3.1-basigin-2 or basigin-2 spe-
cific siRNA was transfected into HO-8910 cells or HO-
8910PM cells, respectively. In vitro examinations revealed
that basigin-2 overexpression was associated with increased
enzymatic activity of MMP-2 and MMP-9, resulting in
increased invasiveness and migration in HO-8910 cells.
Furthermore, our results demonstrated that knockdown of
basigin-2 expression by siRNA impaired the migratory and
invasive abilities and down-regulated the activities of both
MMP-2 and MMP-9 in HO-8910PM cells. These data are
consistent with previous studies [19-32]. Induction of
MMPs activity by basigin is regulated by isoform and
glycosylation pattern. We have previously shown that
basigin-3 was one of the most important isoforms of the
basigin family, and it inhibited hepatocellular carcinoma
cell proliferation, MMP induction, and cell invasion,
probably via hetero-oligomerization with basigin-2 [35].
However, expression pattern of basigin is different in
ovarian cancer. Basigin-4, not basigin-3 was found to
over-express in ovarian tissues besides basigin-2 and
may play more important role on metastasis of ovarian
cancer than basigin-3 cause its higher expression in
HO-8910PM cells. Taken together, overexpression of
basigin-2 increased the secretion of MMP-2/MMP-9
and cancer cell migration and invasion of HO-8910cells, whereas the inhibition caused by basigin-2 siRNA
affected HO-8910PM cell migration and invasion
through MMP-2 and MMP-9 expression. These data
suggest that the suppression of basigin-2 expression has
potential for antimetastatic therapy by inhibiting activity
of MMP-2 and MMP-9.
Conclusions
In summary, this study is the first to examine the expres-
sion patterns of basigin and its isoforms in ovarian cancer
tissues and cell lines. Our study demonstrated that the ex-
pression level of basigin-2 was highly increased in epithelial
ovarian cancer. Moreover, basigin-2 protein expression was
significantly correlated with survival and the expression
level of MMP-2/MMP-9 and malignant metastasis of ovar-
ian cancer. This study further elucidates the molecular
mechanisms underlying invasion and metastasis of ovarian
cancer. These data suggest that basigin-2 may serve as
a promising therapeutic target for ovarian cancer and
that down-regulating basigin-2 could potentially be an
effective therapeutic approach for inhibition of ovarian
cancer progression.
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